Malaria remains the most serious infectious disease and is one of the leading causes of death among children in malaria endemic areas.The development of malaria vaccines has been underway since 1960s.Significant progr...Malaria remains the most serious infectious disease and is one of the leading causes of death among children in malaria endemic areas.The development of malaria vaccines has been underway since 1960s.Significant progress in the development of vaccine has been made in the last decade.On 6 October 2021,World Health Organization recommended widespread use of the RTS,S/AS01 malaria vaccine.The level of acceptance of RTS,S/AS01 malaria vaccine is relatively low in middle-income countries.This might be because of lack of information regarding vaccine implementation in such countries.The proper and efficient execution of the malaria vaccination program necessitates careful consideration of each community's socio-cultural setting.The most prominent RTS,S/AS01 vaccine trial was conducted from 2009 to 2011 in which eleven sites in seven African countries participated.Results of the trial,published in 2015,provided a promising advance in the development of a malaria vaccine for African children.As of 2019,large-scale pilot studies of the vaccine have been conducted in Ghana,Kenya,and Malawi,involving several hundreds of thousands of infants.The RTS,S/AS01 vaccine shows modest efficacy against malaria and has a feasible mode of administration.Although there is increased risk of meningitis,cerebral malaria,pneumonia,anemia,febrile convulsions and gastroenteritis,the vaccine still has a feasible mode of administration and high cost effectiveness and can be easily implemented in resource-limited settings.展开更多
2021年10月,疟疾亚单位疫苗RTS,S/AS01获得世界卫生组织(World Health Organization,WHO)的批准,可以接种于疟疾传播风险较高地区的儿童,以期降低非洲5岁以下儿童因疟疾感染而导致的死亡率.因此,RTS,S/AS01成为了获批的首款疟疾疫苗.时...2021年10月,疟疾亚单位疫苗RTS,S/AS01获得世界卫生组织(World Health Organization,WHO)的批准,可以接种于疟疾传播风险较高地区的儿童,以期降低非洲5岁以下儿童因疟疾感染而导致的死亡率.因此,RTS,S/AS01成为了获批的首款疟疾疫苗.时隔两年,在RTS,S基础上进行改进的R21/Matrix-M疫苗也获得了WHO的批准,成为了第二款获批的疟疾疫苗.RTS,S/AS01(Mosquirix)和R21/Matrix-M两款疫苗的相继获批,让人们看到了对抗疟疾的新希望,因此被入选“Science 2023年度十大科学突破”之一.展开更多
文摘Malaria remains the most serious infectious disease and is one of the leading causes of death among children in malaria endemic areas.The development of malaria vaccines has been underway since 1960s.Significant progress in the development of vaccine has been made in the last decade.On 6 October 2021,World Health Organization recommended widespread use of the RTS,S/AS01 malaria vaccine.The level of acceptance of RTS,S/AS01 malaria vaccine is relatively low in middle-income countries.This might be because of lack of information regarding vaccine implementation in such countries.The proper and efficient execution of the malaria vaccination program necessitates careful consideration of each community's socio-cultural setting.The most prominent RTS,S/AS01 vaccine trial was conducted from 2009 to 2011 in which eleven sites in seven African countries participated.Results of the trial,published in 2015,provided a promising advance in the development of a malaria vaccine for African children.As of 2019,large-scale pilot studies of the vaccine have been conducted in Ghana,Kenya,and Malawi,involving several hundreds of thousands of infants.The RTS,S/AS01 vaccine shows modest efficacy against malaria and has a feasible mode of administration.Although there is increased risk of meningitis,cerebral malaria,pneumonia,anemia,febrile convulsions and gastroenteritis,the vaccine still has a feasible mode of administration and high cost effectiveness and can be easily implemented in resource-limited settings.
文摘2021年10月,疟疾亚单位疫苗RTS,S/AS01获得世界卫生组织(World Health Organization,WHO)的批准,可以接种于疟疾传播风险较高地区的儿童,以期降低非洲5岁以下儿童因疟疾感染而导致的死亡率.因此,RTS,S/AS01成为了获批的首款疟疾疫苗.时隔两年,在RTS,S基础上进行改进的R21/Matrix-M疫苗也获得了WHO的批准,成为了第二款获批的疟疾疫苗.RTS,S/AS01(Mosquirix)和R21/Matrix-M两款疫苗的相继获批,让人们看到了对抗疟疾的新希望,因此被入选“Science 2023年度十大科学突破”之一.
